Oropouche Virus
|
|||||||
Taxonomy |
Bunyaviridae |
||||||
Power |
A pain, but nothing to worry about. |
||||||
OFFENSES |
|||||||
Attacks |
Acute febrile illness ATTACK |
||||||
Outcome |
Arthralgia, myalgia, headache, prostration à no death, rapid recovery |
||||||
Speed |
Quick |
||||||
DEFENSES |
|||||||
Vaccines |
GET SOME SLEEP There is nothing to be done. |
||||||
Behavioral |
|||||||
Treatment |
|||||||
Game Action |
Take 1-2 weeks to rest, take two ATTACKS on immune level |
||||||
One liner |
Watch out! During the rainy season in the steamy Amazon jungle, Oropouche might attack you in a sylvatic cycle involving sloths, monkeys, and jungle mosquitoes! |
Rubella Virus
|
||||||||||
Taxonomy |
Togaviridae; Rubivirus |
|||||||||
Power |
Child or adult: mild Neonate: severe |
|||||||||
OFFENSES |
||||||||||
Attacks |
Rash ATTACK! |
Arthritis ATTACK! |
Brain ATTACK! |
Baby ATTACK! |
||||||
Outcome |
Maculopapular rash, fever, conjunctivitis, sore throat |
Mystery??? Does it cause chronic or recurrent arthritis in you?? |
Postinfectious encephalopathy or encephalomyelitis à 20% fatal |
Mental retardation, motor disability, abnormal posture and movements, neurosensory hearing loss, retinopathy |
||||||
Speed |
Quick to come and quick to go |
|||||||||
DEFENSES |
||||||||||
Vaccines |
Live attenuated; very effective; Administered to pre-school children with measles and mumps vaccine in the United States. Vaccine associated with arthritis. |
|||||||||
Behavioral |
STAY AWAY FROM CHILDREN (read: VECTORS OF DISEASE) WHEN PREGNANT!! |
|||||||||
Treatment |
There is only treatment of complications if they arise. Post-exposure prophylaxis is ineffective |
|||||||||
Game Action |
Opponent roles die. If they role a 1, they are prenatally infected and forfeit their BRAIN POWER! If they role 2,3,4,5 they are infected as a child and LOSE A TURN! If they role a 6 they suffer complications and forfeit their ability to ATTACK! |
|||||||||
One liner |
Rubella is gonna infect ya. But vaccination across the nation will prevent the inflammation. |
Hepatitis Delta Virus
|
||||||||
Description of virus |
The Delta Agent: Must have an associated HBV infection. |
|||||||
Power |
Strong! |
|||||||
OFFENSES |
||||||||
Attacks |
COINFECTION ATTACK! (infection with HDV and HBV at once) |
SUPERINFECTION ATTACK!! (chronic HBV infection then HDV infection) |
||||||
Outcome |
Acute type D hepatitis! Appearance of preicteric phase with lethargy, anorexia, and nausea. Followed by icteric phase and jaundice including clay-colored stool and dark urine. |
Possible fulminant hepatitis! Accompanying jaundice, hepatic encephalopathy is manifested by changes in personality, sleep, confusion, and difficulty concentrating. In severe there may be abnormal behavior, somnolence, and coma. Death may follow 80% of the time. Chronic hepatitis could also happen! Often resulting in cirrhosis, a high proportion die of hepatic failure. |
||||||
Speed |
3-7 week incubation period; short and lingering symptoms |
|||||||
DEFENSES |
||||||||
Vaccines |
Vaccination against Hepatitis B virus (already in use) will stop any infection of HDV because HDV uses the envelope proteins of HBV and cannot infect cells without HBV around. There are tests to vaccinate against HDV in cronic HBV patients. |
|||||||
Behavioral |
Screen and exclude blood donors with markers for HBV. Dont use dirty needles. Use condoms. |
|||||||
Treatment |
There is no specific treatment of HDV. Alpha-interferon can be used to inhibit HDV replication, but no long term solution has been found. For cases of fulminant and chronic hepatitis, orthotopic liver transplantation may be necessary. |
|||||||
Game Action |
If your opponent has a HBV card in their already-played deck, they have SUPERINFECTION and lose the game. If your opponent has a HBV card in their not-yet-played deck, they have COINFECTION and lose two turns. If your opponent has no HBV card, you lose a turn. |
|||||||
One liner |
Hepatitis Delta Virus. Your past is everything. |
Fields, Bernard. Virology. Philadelphia: Lippincott-Raven Publications, 1996. pp 899-921, 1485, 2819-2827.